October 17, 2011
The Case Comprehensive Cancer Center (Case CCC), in partnership with The Ohio State University (OSU), Georgetown University, and Roswell Park, is pleased to announce the receipt of an N01 consortium contract to conduct Phase 2 and early clinical trials of National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) agents to determine their clinical benefit.
OSU, which previously held an N01, will serve as the lead site on this contract. The Case CCC team will be led by Dr. Neal Meropol, along with UH Site PI Dr. Afshin Dowlati and Cleveland Clinic Site PI Dr. Robert Dreicer.
"Only seven centers in the United States received an N01 contract," said Dr. Stan Gerson. "Along with the U01 previously awarded to Afshin Dowlati, this award places us in a small group of NCI-designated cancer centers with this dual recognition as a center focused on innovative therapeutics."